Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Shares of AstraZeneca are up 1.51% at $165.79. The company is worth $257.12B, number 56 out of 300 on our list.
The 52-week range is $144.88 to $209.11. Today's price is about 33% of the way from the low to the high. Holders are ahead 11.9% over twelve months, but down 8.8% across the last three months.
Price is above the 50-day average ($163.84) but below the 200-day ($181.26); RSI is 54, and the last 30 sessions moved at roughly 21% annualized volatility.
For the quarter ended Jun 2026 it reported $15.38B in revenue, up 6.4% from a year earlier, with $2.51B of net profit (a 17.0% margin).
Valuation works out to 24.8 times trailing earnings, 73% below its five-year average of 91.1. The median for its industry group is 20.4.
16 analysts follow the stock and the average call is "buy". The mean target, $218.59, sits 31.8% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
AstraZeneca is a British-Swedish drugmaker with big franchises in cancer, heart and metabolic disease, respiratory conditions and rare diseases.
What tends to move it. Its oncology drugs carry the growth, and the market follows late-stage trial results and any U.S. drug pricing changes.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +1.5% | Bullish |
| Price vs 50-day average | +1.2% | Bullish |
| Price vs 200-day average | -8.5% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 53.9 | Bullish |
| MACD (12,26,9) | 0.61 | Bullish |
| Bollinger band position | 70% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
Quarter 2025/FY
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 13th percentile, 5-year average 91.1x
#1844 of 2977 stocks by PE (1 = cheapest)
Near the bottom of its 5-year range · 14th percentile, 5-year average 5.8x
#4296 of 5303 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 15th percentile, 5-year average 4.7x
#3580 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$106.84M (6 inflow days, 14 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 15.2% a year.
$165.79 is the latest print for AZN, a move of +1.51% against yesterday's close of $163.33. Today's low and high so far: $162.92 and $166.25.
Equity value comes to $257.12B at the current price. By that measure it is number 56 of the 300 names in our coverage.
Buyers pay 24.8 times the last twelve months of profit (EPS $6.54). Averaged over five years the multiple has been 91.1, and today's level ranks in the 13th percentile of its own history.
The year's floor is $144.88 and the ceiling $209.11. Shares are 20.7% away from that ceiling.
It does. Payouts over the past twelve months work out to a 1.91% yield; the latest ex-dividend date was August 7, 2026.
Of 16 analysts, 88% say buy, 6% hold and 6% sell. Price targets average $218.59, with the most cautious at $155.10 and the most optimistic at $272.43.
AstraZeneca is a British-Swedish drugmaker with big franchises in cancer, heart and metabolic disease, respiratory conditions and rare diseases.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.